Medications used for weight loss, such as Ozempic, Wegovy, Mounjaro, and Zepbound, are taking over the pharmaceutical industry. While Eli Lilly and Novo Nordisk are the big players in diabetes and obesity care thanks to their glucagon-like peptide-1 (GLP-1) agonists, there are a number of companies looking to dethrone the industry stalwarts.

For the most part, competitors are investing hefty sums into research and development to bring their own GLP-1 drugs to market.

Continue reading

Source Fool.com